Shah, Sanjiv J., Borlaug, Barry A., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Chung, Eugene S., Leon, Martin B., REDUCE LAP-HF II investigators,, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter S., Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M.. The Lancet Publishing Group; 2022. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.

Gustafsson, Finn, Petrie, Mark C., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G. F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Komtebedde, Jan, Solomon, Scott D., Shah, SJ, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L.. Elsevier; 2024. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.